Make it your homepage |   E-mail: Subscribe Unsubscribe

China in 30 minutes: Week in China celebrates a milestone

This text is replaced by the Flash movie.

Thursday, May 24, 2012
News Making Money

Research-based pharmaceutical industry pledges 14 billion treatments

02/02/2012 06:03 (112 Day 03:45 minutes ago)

The FINANCIAL -- The research-based pharmaceutical industry announced donations of 14 billion treatments this decade to support the elimination or control of nine key neglected tropical diseases.

ADVERTISEMENT

 

According to IFPMA, averaging 1.4 billion treatments annually, the donations build upon companies’ existing medicines donation programmes which already reach millions of people around the world.

 

Today’s announcement comes in conjunction with an NTD collaboration comprised of pharmaceutical companies, the Bill & Melinda Gates Foundation, the US and UK governments, international organisations, and endemic countries’ national governments.

 

At least one billion people worldwide — one person in seven — suffer from NTDs. Each year NTDs disproportionately kill or disable millions of poor people primarily in tropical and subtropical areas.

 

These donations follow a World Health Organisation announcement of new targets for NTDs whose elimination or control is achievable with adequate supply and distribution of the relevant medicines. For maximum impact, these donations focus on those nine NTDs that represent more than 90 percent of the global NTD burden.In addition to medicine donations, the research-based pharmaceutical industry supports the fight against

 

NTDs with capacity-building efforts in developing countries and medical innovation. The research-based
pharmaceutical industry was the second largest funder of R&D for neglected diseases in 2010, reaching
more than USD 500 million.

 

 

Make Your Comment

Add NewSearchRSS
Only registered users and facebook social network members can write comments!

This text is replaced by the Flash movie.
This text is replaced by the Flash movie.












Developed by Aleksandre Chiabrishvili

Design built by Creo Group